Intriguingly, previous studies have shown that the production of anti‐neutral glycolipid (NGL) autoantibody (which leads to the activation complement system) has been observed in experimental and human Gaucher disease (GD) and amyotrophic lateral sclerosis (ALS) transgenic mice ([1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13], see [14] for review). Here, ERBB2 is linked to Gaucher disease.